These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 19668235

  • 1. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [Abstract] [Full Text] [Related]

  • 2. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 3. Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.
    George B, Kerridge I, Gilroy N, Huang G, Hertzberg M, Gottlieb D, Bradstock K.
    Bone Marrow Transplant; 2010 May 01; 45(5):849-55. PubMed ID: 19915635
    [Abstract] [Full Text] [Related]

  • 4. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia.
    Schetelig J, Oswald O, Steuer N, Radonic A, Thulke S, Held TK, Oertel J, Nitsche A, Siegert W.
    Bone Marrow Transplant; 2003 Oct 01; 32(7):695-701. PubMed ID: 13130317
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R, Martino R, Sureda A, Labeaga R, Brunet S, Sierra J, Rabella N.
    Bone Marrow Transplant; 1998 Nov 01; 22(9):899-904. PubMed ID: 9827819
    [Abstract] [Full Text] [Related]

  • 6. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Cámara R, López J, López-Aldeguer N, Hernández-Boluda JC, Remigia MJ, Garcia-Noblejas A, Gimeno C, Navarro D.
    Bone Marrow Transplant; 2010 Mar 01; 45(3):543-9. PubMed ID: 19617905
    [Abstract] [Full Text] [Related]

  • 7. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A, Yasumoto A, Yamamoto S, Sugita J, Kondo T, Onozawa M, Kahata K, Endo T, Ota S, Sato N, Takahata M, Okada K, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):679-85. PubMed ID: 19450752
    [Abstract] [Full Text] [Related]

  • 8. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R, Ross S, Hüsing J, Ottinger H, Elmaagacli A, Roggendorf M, Schaefer UW, Runde V.
    Bone Marrow Transplant; 2000 Mar 01; 25(6):665-72. PubMed ID: 10734302
    [Abstract] [Full Text] [Related]

  • 9. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH, Chlebicka NL, Low JG, Chong TY, Chan KP, Goh YT.
    Transpl Infect Dis; 2008 Oct 01; 10(5):325-32. PubMed ID: 18627578
    [Abstract] [Full Text] [Related]

  • 10. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
    Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K, Ohnishi M, Niiya H, Nakai K, Takeuchi T, Kawahigashi N, Shoji N, Ogasawara T, Tanosaki R, Kobayashi Y, Tobinai K, Kami M, Mori S, Suzuki R, Kunitoh H, Takaue Y.
    Bone Marrow Transplant; 2001 Feb 01; 27(4):437-44. PubMed ID: 11313674
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.
    Mohty M, Mohty AM, Blaise D, Faucher C, Bilger K, Isnardon D, Sainty D, Gastaut JA, Viens P, Olive D, Gaugler B.
    Bone Marrow Transplant; 2004 Apr 01; 33(8):839-46. PubMed ID: 14767500
    [Abstract] [Full Text] [Related]

  • 12. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P.
    Bone Marrow Transplant; 2001 Oct 01; 28(8):765-8. PubMed ID: 11781628
    [Abstract] [Full Text] [Related]

  • 13. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H, Eljed H, Greco A, Lakhal A, Torjman L, Abdelkefi A, Ben Othmen T, Ladeb S, Slim A, Zouari B, Abdeladhim A, Ben Hassen A.
    Transpl Infect Dis; 2007 Mar 01; 9(1):16-21. PubMed ID: 17313466
    [Abstract] [Full Text] [Related]

  • 14. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ, Xu LP, Ren HY, Zhang YC, Guo NL, Lu DP.
    Zhonghua Yi Xue Za Zhi; 2003 May 10; 83(9):766-9. PubMed ID: 12899755
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors.
    Yoon HS, Lee JH, Choi ES, Seo JJ, Moon HN, Kim MN, Im HJ.
    Pediatr Transplant; 2009 Nov 10; 13(7):898-905. PubMed ID: 19032414
    [Abstract] [Full Text] [Related]

  • 16. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D, Larcher C, Kircher B, Eibl G, Nussbaumer W, Gunsilius E, Haun M, Grünewald K, Gastl G.
    Ann Hematol; 2003 Oct 10; 82(10):621-7. PubMed ID: 12920570
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, Maruyama F, Wakita A, Kitaori K, Yano K, Hamaguchi M, Hamajima N, Morishima Y, Kodera Y, Sao H, Morishita Y.
    Bone Marrow Transplant; 2003 Oct 10; 32(8):801-7. PubMed ID: 14520425
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M.
    Bone Marrow Transplant; 2002 Apr 10; 29(7):599-606. PubMed ID: 11979310
    [Abstract] [Full Text] [Related]

  • 19. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Müller H, Freigassner M, Allmayr T, Hipmair G.
    Wien Klin Wochenschr; 1995 Apr 10; 107(23):718-22. PubMed ID: 8560893
    [Abstract] [Full Text] [Related]

  • 20. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A.
    Bone Marrow Transplant; 2004 May 10; 33(9):931-5. PubMed ID: 15034541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.